Summary

The Europe alpha and beta emitters based radiopharmaceuticals market is expected to reach USD 465.84 million by 2032 from USD 215.99 million in 2024, growing with a substantial CAGR of 10.1% in the forecast period of 2025 to 2032.

Market Segmentation:
Europe Alpha and Beta Emitters Based Radiopharmaceuticals Market, By Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes), Country (Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Netherlands, Poland, Norway, Austria, Ireland, and Rest of Europe) - Industry Trends and Forecast to 2032
Overview of Europe Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics:
Drivers
• Increased efficacy of targeted alpha and beta therapies
• Growing adoption of theranostics in personalized medicine
Restraints
• Supply chain and scalability challenges from short isotope half-lives
• Stringent regulatory landscape limiting market flexibility
Opportunities
• Surge in R&D activity expanding radiopharmaceutical applications
• Expansion of Lu-177-PSMA therapy in prostate cancer treatment
Market Players:
The key players operating in the Europe alpha and beta emitters based radiopharmaceuticals market are:
• Novartis AG
• Eckert & Ziegler
• ITM Isotope Technologies Munich SE
• SHINE Technologies, LLC
• Actinium Pharmaceuticals, Inc.
• ARICEUM THERAPEUTICS
• Bayer AG
• Curium
• Isotopia
• Lantheus
• Lilly
• Oncoinvent
• Orano Group
• Telix Pharmaceuticals Limited
• Terthera

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 35
1.4 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 CURRENCY AND PRICING 42
2.5 DBMR TRIPOD DATA VALIDATION MODEL 43
2.6 MULTIVARIATE MODELLING 46
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.8 DBMR MARKET POSITION GRID 48
2.9 VENDOR SHARE ANALYSIS 49
2.10 END USER MARKET COVERAGE GRID 50
2.11 SECONDARY SOURCES 51
2.12 ASSUMPTIONS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHT 58
4.1 PORTER’S FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
4.3 PIPELINE 61
4.4 SUPPLY CHAIN ECOSYSTEM 66
4.4.1 PROMINENT COMPANIES 66
4.4.2 SMALL & MEDIUM SIZE COMPANIES 66
4.4.3 END USERS 66
4.5 INDUSTRY INSIGHTS 67
4.5.1 MICRO AND MACRO ECONOMIC FACTORS 67
4.5.2 KEY PRICING STRATEGIES 68
4.6 MARKETED DRUG ANALYSIS 69
4.6.1 DRUG 69
4.6.1.1 BRAND NAME 69
4.6.1.2 GENERIC NAME 69
4.6.2 THERAPEUTIC INDICATION 69
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG 69
4.6.4 DRUG PRIMARY INDICATION 69
4.6.5 MARKET STATUS 69
4.6.6 MEDICATION TYPE 70
4.6.7 DRUG DOSAGE FORM 70
4.6.8 DOSAGES AVAILABILITY 70
4.6.9 PACKAGING TYPE 70
4.6.10 DRUG ROUTE OF ADMINISTRATION 70
4.6.11 DOSING FREQUENCY 70
4.6.12 DRUG INSIGHT 70
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES 71
4.6.13.1 FORECAST MARKET OUTLOOK 71
4.6.13.2 CROSS COMPETITION 71
4.6.13.3 THERAPEUTIC PORTFOLIO 71
4.6.13.4 CURRENT DEVELOPMENT SCENARIO 71
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS 72
4.7.1 OVERVIEW 72
4.7.2 TARIFF STRUCTURES 72
4.7.2.1 EUROPE VS. REGIONAL TARIFF STRUCTURES 72
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 72
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES 72
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 72
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 73
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 73
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 73
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 73
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 73
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 73
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 73
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 73
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 74
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 74
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 74
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 74
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 74
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 74
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 74
4.9 EPIDEMIOLOGY OVERVIEW 75
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER 75
4.9.2 TREATMENT RATE 76
4.9.3 MORTALITY RATE 76
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 77
4.9.5 PATIENT TREATMENT SUCCESS RATES 77
5 REGULATORY FRAMEWORK 79
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 82
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 82
5.1.2 REGULATORY APPROVAL PATHWAYS 82
5.1.3 LICENSING AND REGISTRATION 83
5.1.4 POST-MARKETING SURVEILLANCE 83
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 83
6 MARKET OVERVIEW 87
6.1 DRIVERS 89
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES 89
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE 89
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES 90
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND 91
6.2 RESTRAINTS 92
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES 92
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY 92
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE 93
6.3 OPPORTUNITIES 94
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS 94
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT 95
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION 95
6.4 CHALLENGES 96
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 96
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY 97
7 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 99
7.1 OVERVIEW 100
7.2 BETA EMITTERS 103
7.2.1 LUTETIUM-177 103
7.2.2 TERBIUM-161 103
7.3 ALPHA EMITTERS 104
7.3.1 ACTINIUM-225 104
7.3.2 LEAD -212 104
8 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES 105
8.1 OVERVIEW 106
8.2 REACTOR-PRODUCED ISOTOPES 109
8.3 GENERATOR-PRODUCED ISOTOPES 109
8.4 OTHERS 110
9 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION 111
9.1 OVERVIEW 112
9.2 ONCOLOGY 115
9.2.1 PROSTATE CANCER 116
9.2.2 NEUROENDOCRINE TUMORS 116
9.2.3 LIVER CANCER 116
9.2.4 BRAIN TUMORS 116
9.2.5 BREAST CANCER 116
9.2.6 LEUKEMIA 116
9.3 OTHERS 116
10 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE 117
10.1 OVERVIEW 118
10.2 SMALL MOLECULE LIGANDS 121
10.3 PEPTIDES 121
10.4 MONOCLONAL ANTIBODIES 122
10.5 OTHERS 122
11 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER 123
11.1 OVERVIEW 124
11.2 HOSPITALS 127
11.2.1 ONCOLOGY CENTERS 127
11.2.2 NUCLEAR MEDICINE DEPARTMENTS 127
11.3 RADIOPHARMACIES 128
11.4 RESEARCH INSTITUTES 128
12 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION 129
12.1 EUROPE 131
12.1.1 GERMANY 135
12.1.2 U.K. 138
12.1.3 FRANCE 141
12.1.4 ITALY 144
12.1.5 SPAIN 147
12.1.6 POLAND 150
12.1.7 RUSSIA 153
12.1.8 NORWAY 156
12.1.9 TURKEY 159
12.1.10 AUSTRIA 162
12.1.11 IRELAND 165
12.1.12 NETHERLANDS 168
12.1.13 SWITZERLAND 171
12.1.14 REST OF EUROPE 174
13 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 175
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS 176
15 COMPANY PROFILES 177
15.1 NOVARTIS AG 177
15.1.1 COMPANY SNAPSHOT 177
15.1.2 REVENUE ANALYSIS 178
15.1.3 COMPANY SHARE ANALYSIS 178
15.1.4 PRODUCT PORTFOLIO 179
15.1.5 RECENT DEVELOPMENTS 179
15.2 ECKERT & ZIEGLER 180
15.2.1 COMPANY SNAPSHOT 180
15.2.2 REVENUE ANALYSIS 180
15.2.3 COMPANY SHARE ANALYSIS 181
15.2.4 PRODUCT PORTFOLIO 181
15.2.5 RECENT DEVELOPMENTS 182
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE 183
15.3.1 COMPANY SNAPSHOT 183
15.3.2 COMPANY SHARE ANALYSIS 183
15.3.3 PRODUCT PORTFOLIO 184
15.3.4 RECENT DEVELOPMENT 184
15.4 SHINE TECHNOLOGIES, LLC 185
15.4.1 COMPANY SNAPSHOT 185
15.4.2 COMPANY SHARE ANALYSIS 185
15.4.3 PRODUCT PORTFOLIO 186
15.4.4 RECENT DEVELOPMENT 186
15.5 ACTINIUM PHARMACEUTICALS, INC. 187
15.5.1 COMPANY SNAPSHOT 187
15.5.2 PIPELINE PRODUCT PORTFOLIO 187
15.5.3 RECENT DEVELOPMENTS 188
15.6 ALPHA TAU MEDICAL LTD. 189
15.6.1 COMPANY SNAPSHOT 189
15.6.2 PIPELINE PRODUCT PORTFOLIO 189
15.6.3 RECENT DEVELOPMENT 189
15.7 ARICEUM THERAPEUTICS 190
15.7.1 COMPANY SNAPSHOT 190
15.7.2 PIPELINE PRODUCT PORTFOLIO 190
15.7.3 RECENT DEVELOPMENT 190
15.8 BAYER AG 191
15.8.1 COMPANY SNAPSHOT 191
15.8.2 REVENUE ANALYSIS 191
15.8.3 PIPELINE PRODUCT PORTFOLIO 192
15.8.4 RECENT DEVELOPMENT 192
15.9 CURIUM 193
15.9.1 COMPANY SNAPSHOT 193
15.9.2 PIPELINE PRODUCT PORTFOLIO 193
15.9.3 RECENT DEVELOPMENT 193
15.10 IONETIX CORPORATION 194
15.10.1 COMPANY SNAPSHOT 194
15.10.2 PIPELINE PRODUCT PORTFOLIO 194
15.10.3 RECENT DEVELOPMENT 194
15.11 ISOTOPIA 195
15.11.1 COMPANY SNAPSHOT 195
15.11.2 PIPELINE PRODUCT PORTFOLIO 195
15.11.3 RECENT DEVELOPMENT 195
15.12 LANTHEUS 196
15.12.1 COMPANY SNAPSHOT 196
15.12.2 REVENUE ANALYSIS 196
15.12.3 PIPELINE PRODUCT PORTFOLIO 197
15.12.4 RECENT DEVELOPMENT 198
15.13 LILLY 199
15.13.1 COMPANY SNAPSHOT 199
15.13.2 REVENUE ANALYSIS 199
15.13.3 PIPELINE PRODUCT PORTFOLIO 200
15.14 NIOWAVE 201
15.14.1 COMPANY SNAPSHOT 201
15.14.2 PIPELINE PRODUCT PORTFOLIO 201
15.14.3 RECENT DEVELOPMENT 201
15.15 NMR 202
15.15.1 COMPANY SNAPSHOT 202
15.15.2 PIPELINE PRODUCT PORTFOLIO 202
15.15.3 RECENT DEVELOPMENT 202
15.16 ONCOINVENT 203
15.16.1 COMPANY SNAPSHOT 203
15.16.2 PIPELINE PRODUCT PORTFOLIO 203
15.16.3 RECENT DEVELOPMENT 203
15.17 ORANO GROUP 204
15.17.1 COMPANY SNAPSHOT 204
15.17.2 REVENUE ANALYSIS 204
15.17.3 PIPELINE PRODUCT PORTFOLIO 205
15.17.4 RECENT DEVELOPMENT 206
15.18 RADIOPHARM THERANOSTICS LIMITED 207
15.18.1 COMPANY SNAPSHOT 207
15.18.2 PIPELINE PRODUCT PORTFOLIO 207
15.18.3 RECENT DEVELOPMENT 208
15.19 TELIX PHARMACEUTICALS LIMITED 209
15.19.1 COMPANY SNAPSHOT 209
15.19.2 REVENUE ANALYSIS 209
15.19.3 PIPELINE PRODUCT PORTFOLIO 210
15.19.4 RECENT DEVELOPMENT 211
15.20 TERTHERA 212
15.20.1 COMPANY SNAPSHOT 212
15.20.2 PIPELINE PRODUCT PORTFOLIO 212
15.20.3 RECENT DEVELOPMENT 212
15.20.4 RECENT DEVELOPMENT 212
16 QUESTIONNAIRE 213
17 RELATED REPORTS 216